Analytical performance of a new chemiluminescent phenytoin (ACS:180) assay

被引:6
作者
Dasgupta, A
Datta, P
Redlich, G
Limmany, A
机构
[1] UNIV NEW MEXICO,DEPT PATHOL,HLTH SCI CTR,CLIN LABS,ALBUQUERQUE,NM 87131
[2] CIBA CORNING DIAGNOST CORP,MEDFIELD,MA
关键词
ACS-phenytoin; fluorescence polarization;
D O I
10.1097/00007691-199704000-00013
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The authors, as a beta testing site, evaluated the ACS:180-phenytoin chemiluminescent assay (Ciba-Corning Diagnostics Corp., Medfield, MA, U.S.A.) by comparing its performance with a widely used fluorescence assay for phenytoin (Abbott Laboratories, Abbott Park, IL, U.S.A.). The ACS:180-phenytoin assays were run on a ACS-180 analyzer and fluorescence polarization assays on a TDx analyzer. The within-run precision for ACS-phenytoin assay were 2.9% was determined using controls obtained from Ciba-Corning The CVs were 2.9% for low control ((X) over bar = 5.5, SD = 0.16 mu g/ml, n = 10), 2.8% for the medium control ((X) over bar = 13.4, SD = 0.37 mu g/ml, n = 10), and 2.7% for the high control ((X) over bar = 24.6, SD = 0.66 mu g/ml, n = 10), The corresponding between run precisions were 4.1% for the low control ((X) over bar 5.4, SD = 0.22 mg/ml, n = 10), 3.1% for the medium control ((X) over bar = 13.8, SD = 0.43 mg/ml, n = 10), and 2.9% ((X) over bar = 24.5, SD = 0.70 mg/ml, n = 10) for the high control. The assay was linear from 0.5 to 40 mu g/ml of serum phenytoin concentrations with a detection limit of 0.24 mu g/ml. The recoveries were 93-97% for concentrations of phenytoin of 5-30 mu g/ml. They also compared 111 serum specimens collected from patients receiving phenytoin, The concentrations of phenytoin ranged from none detected to 32.4 mu g/ml. Using fluorescence polarization assay as x-axis (reference method) and ACS:180-phenytoin assay as y-axis, they obtained the following regression line: y = 1.0x - 0.26, r = 0.993. They conclude that the ACS-phenytoin assay has a good precision and that the results correlate well with the fluorescence polarization assay.
引用
收藏
页码:191 / 194
页数:4
相关论文
共 13 条
  • [1] INFLUENCES OF PHENYTOIN ON FUNDAMENTAL ELECTRICAL-PROPERTIES OF SIMPLE NEURAL SYSTEMS
    AYALA, GF
    JOHNSTON, D
    [J]. EPILEPSIA, 1977, 18 (03) : 299 - 307
  • [2] BURNI J, 1986, TXB CLIN APPL THERAP, P253
  • [3] Delgado-Escueta A V, 1980, Adv Neurol, V27, P377
  • [4] SERIAL FREE AND PLASMA VALPROIC ACID AND PHENYTOIN MONITORING AND DRUG-INTERACTIONS
    HAIDUKEWYCH, D
    RODIN, EA
    [J]. THERAPEUTIC DRUG MONITORING, 1981, 3 (03) : 303 - 307
  • [5] BIOAVAILABILITY OF 11 PHENYTOIN PRODUCTS
    MELIKIAN, AP
    STRAUGHN, AB
    SLYWKA, GWA
    WHYATT, PL
    MEYER, MC
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1977, 5 (02): : 133 - 146
  • [6] Sodium diphenyl hydantoinate in the treatment of convulsive disorders
    Merritt, HH
    Putnam, TJ
    [J]. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1938, 111 : 1068 - 1073
  • [7] Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180
    Miller, JJ
    Straub, RW
    Valdes, R
    [J]. THERAPEUTIC DRUG MONITORING, 1996, 18 (01) : 65 - 72
  • [8] MULLEN PW, 1978, CLIN PHARMACOL THER, V23, P228
  • [9] PUTMAN TJ, 1937, SCIENCE, V85, P525
  • [10] CLINICAL PHARMACOKINETICS OF PHENYTOIN
    RICHENS, A
    [J]. CLINICAL PHARMACOKINETICS, 1979, 4 (03) : 153 - 169